| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BX-912 | GDSC1000 | pan-cancer | AAC | 0.0061 | 0.8 |
| mRNA | Repligen 136 | CTRPv2 | pan-cancer | AAC | -0.0075 | 0.8 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | -0.0069 | 0.8 |
| mRNA | KU-55933 | CTRPv2 | pan-cancer | AAC | -0.0074 | 0.8 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.0072 | 0.8 |
| mRNA | temsirolimus | GDSC1000 | pan-cancer | AAC | 0.0064 | 0.9 |
| mRNA | AZD8055 | CTRPv2 | pan-cancer | AAC | 0.0068 | 0.9 |
| mRNA | selumetinib:BRD-A02303741 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0069 | 0.9 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | 0.0069 | 0.9 |
| mRNA | GSK1059615 | CTRPv2 | pan-cancer | AAC | 0.0086 | 0.9 |